Abstract: For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively. The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.

Abstract: The invention relates to the use of a bacterial mixture for the prevention and improvement of the state of ungulates suffering from pathologies involving a parasitic or bacterial infection of the foot, said composition comprising: at least one strain of bacteria of the genus Bacillus, and at least one lactic acid bacterium.

Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. aureus (MRSA) and vancomycin intermediate S. aureus (VISA).

Abstract: The present invention relates to methods and systems for determining the antibiotic-resistance status of microorganisms. The invention further provides methods for determining the antibiotic-resistance status of microorganisms in situ within a single system.

Abstract: The present disclosure relates to a method for regulating expression of protein of interest in Bacillus subtilis, and belongs to the technical field of genetic engineering. The method comprises: using Bacillus subtilis as an expression host, adding the N-terminal nucleotide sequence coding the first 15 amino acids of the endogenous protein before the coding gene of the protein of interest or modifying the original N-terminal nucleotide sequence coding the first 15 amino acids, and performing free expression in plasmid, thereby regulating expression of the protein of interest in Bacillus subtilis, and even regulating the expression difference in different growth phases and the expression level.

Abstract: This invention relates to a composition for additives which can be employed in animal feeds, or as growth promoters, or as nutraceuticals, or as prebiotics, or as additives for the control and prophylaxis of pathogenic bacteria in the intestinal tract of animals or farmed animals. An immunomodulatory and promoter composition for controlling the population of undesirable bacteria of the intestinal microbiota, comprising the components indicated below: (a) Fructooligosaccharides (FOS); (b) Galacto-oligosaccharides (GOS); (c) Mannan-oligosaccharides (MOS); (d) 1,3 and 1,6 Beta-glucans.

Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.

Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.

Abstract: The present invention relates to the preparation and use in primates of whole organismvaccines in which the MEP pathway is disrupted such that synthesis of HMBPP by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active MEP pathway are used in vaccine methods, the ?? T cell response dominates, potentially clearing the vaccine strain via ?? T cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of CD4+ and CD8+ ?? T cell responses, specific for listerial-encoded antigens. By disrupting the MEP pathway, activation and expansion of ?? T cells is limited in the recipient primate, resulting in resulting in an increase in the magnitude and duration of inflammation and in the magnitude and duration of antigen presentation by the cellular vaccine.

Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.

Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.

Abstract: The present invention discloses a procedure to produce a monomeric and functional form of Bordetella sp, especially B. pertussis, CyaA toxin that can be stably maintained in this functional monodisperse state, even in the absence of any chaotropic agent.

Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.

Abstract: Provided are peptides suitable for early detection of active M. tuberculosis (Mtb) infection in immunocompromised individuals. The peptides can form complexes with antibodies directed to Mtb antigens MS, MPT51, ESAT6 or CFPIO. Also provided are methods for detected of complexes of the peptides and the antibodies. The presence of complexes aids in predicting risk in immunocompromised individuals of developing active tuberculosis.

Abstract: Microparticles include a matrix of an encapsulating material, in which are dispersed particles of a low melting point fat and a bioactive material, such as one or more probiotic bacteria. The microparticles are formed by preparing an emulsion of melted low melting point fat in an aqueous mixture of the encapsulating material, cooling the emulsion below the melting point of the low melting point fat, dispersing the bioactive material in the emulsion and spray drying the emulsion. The particles of solid low melting point fat are believed to protect the bioactive material from heat damage during the spray drying process.

Abstract: Methods for detecting microorganisms, in particular detection of bacteria and methods for measuring enzyme activity, such as Deoxyribonucleic acid (DNA) polymerase activity are disclosed. The aforesaid methods include, but are not limited to such methods performed on microbial crude lysates, useful for determining microbial enzyme activities, which can be linked to amplification signal generators such as real-time Polymerase Chain Reaction (PCR) techniques, thereby enabling determination of microbial pathogens in samples such as unpurified blood and other body fluids. Moreover, the disclosed embodiments also relate to reagents for use in such methods, and to test kits comprising such reagents for carrying out the methods.

Abstract: The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a PglLComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using PglLComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.

Abstract: The present invention relates to an oral universal influenza vaccine comprising recombinant lactic acid bacteria which express proteins including but not limited to ferritin protein plus highly-conserved stem fragment of hemagglutinin (HA) proteins expressed in all known influenza viruses. The present invention also relates to the recombinant protein comprising the highly-conserved stem fragment of HA and ferritin proteins.

Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the ?-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to ?-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.